FIELD: medicine.
SUBSTANCE: group of inventions relates to combination therapy targeting CD38 and TGF-β. The following is provided: the methods of treating multiple myeloma in a human patient using a combination of anti-CD38 antibodies that contains HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 containing the following amino acid sequences SEQ ID NO: 15–20, respectively, and anti-TGF-β an antibody or antigen-binding fragment thereof, which contains HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 with the amino acid sequences of the following SEQ ID NO: 5–10 respectively.
EFFECT: antibody to TGF-β may block the ability of TGF-β to attenuate the antitumor effect of anti-CD38 antibody, thereby providing effective treatment for multiple myeloma, including those resistant to one or more other CD38-targeting therapies.
21 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| TGF-BETA RECEPTOR ECTODOMAIN FUNCTIONS AND THEIR USE | 2018 |
|
RU2797464C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ANTI-GARP-TGF-β-ANTIBODIES | 2018 |
|
RU2767784C2 |
